Longeveron (NASDAQ:LGVN) Upgraded at Roth Capital

Roth Capital upgraded shares of Longeveron (NASDAQ:LGVN) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

A number of other brokerages also recently weighed in on LGVN. Maxim Group cut their price target on shares of Longeveron from $15.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 27th. Roth Mkm began coverage on shares of Longeveron in a report on Friday. They issued a “buy” rating and a $10.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Longeveron in a report on Monday, November 25th.

Longeveron Stock Up 10.6 %

LGVN stock opened at $2.08 on Thursday. The company has a market capitalization of $30.87 million, a P/E ratio of -0.33 and a beta of 0.31. The company has a 50-day simple moving average of $2.02 and a 200 day simple moving average of $2.17. Longeveron has a fifty-two week low of $0.77 and a fifty-two week high of $23.90.

Longeveron (NASDAQ:LGVN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.19. Longeveron had a negative net margin of 967.49% and a negative return on equity of 142.43%. The business had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.34 million. During the same quarter in the prior year, the company posted ($2.80) earnings per share. Equities analysts anticipate that Longeveron will post -3.47 EPS for the current year.

Institutional Trading of Longeveron

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in shares of Longeveron in the 2nd quarter valued at about $236,000. Geode Capital Management LLC increased its stake in Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares during the period. Finally, State Street Corp acquired a new position in Longeveron in the 3rd quarter valued at approximately $29,000. 10.01% of the stock is owned by institutional investors and hedge funds.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.